FDA Places Suicide Warning on Paxil
In light of a recent study indicating a higher rate of suicide and suicide attempt with Paxil over a placebo for treatment of psychiatric disorder including Major Depressive Disorder, the FDA and Paxil maker GlaxoSmithKline updated their warning label to include suicide.
This warning is long in coming, especially in light of the similar warning directed towards adolescents and children put on Paxil last year.
This new warning, coupled with the teratogenic effects recently uncovered, raises serious questions about the benefit/risk ratio of this drug.
Read the FDA's statement here.
Post A Comment / Question